Skip to content
Exclusive CEO Interviews
Press Releases profile photo

Press Releases

Would you like us to consider a press release for publication? Please email david@onyxnewsroom.com.

Sinaptica Therapeutics Completes Scientific Advisory Board, Bringing Together Leading Voices Across Patients, Science, Medicine, and Commercial Strategy

Sinaptica Therapeutics Completes Scientific Advisory Board, Bringing Together Leading Voices Across Patients, Science, Medicine, and Commercial Strategy

✨ Onyx Summary Sinaptica Therapeutics announced the completion of its Scientific Advisory Board, assembling experts across neuroscience, clinical development, neuromodulation, patient advocacy, and commercialization to guide the company through its upcoming pivotal Alzheimer’s disease trial. The expanded board strengthens Sinaptica’s strategic positioning at a key inflection point, supporting clinical

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

✨ Onyx Summary Geron Corporation granted stock options covering 320,000 shares to a newly hired employee as an inducement award, with options priced at the December 17, 2025 closing share price and vesting over four years in accordance with Nasdaq rules and the company’s inducement equity plan. FOSTER CITY,

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

✨ Onyx Summary Perspective Therapeutics announced that Chief Executive Officer Thijs Spoor will present at the J.P. Morgan Healthcare Conference on January 14, 2026, in San Francisco. SEATTLE, Dec. 18, 2025 – Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering

Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference

Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference

✨ Onyx Summary Legend Biotech Corporation announced that CEO Ying Huang will present a company update at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, with a live webcast and replay available via the company’s investor relations website. SOMERSET, N.J.,Dec. 17, 2025 – Legend Biotech

ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer

ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer

✨ Onyx Summary ImmunityBio reported long-term Phase 2/3 QUILT-3.032 data showing that ANKTIVA plus BCG delivered durable disease-free, progression-free, and disease-specific survival, with high cystectomy avoidance through 36 months in patients with BCG-unresponsive high-grade papillary-only non-muscle invasive bladder cancer. Published

Kyverna Therapeutics Announces Proposed Public Offering of Common Stock

Kyverna Therapeutics Announces Proposed Public Offering of Common Stock

✨ Onyx Summary Kyverna Therapeutics announced the launch of an underwritten public offering of $100 million of common stock, with an option for underwriters to purchase up to an additional $15 million of shares, subject to market conditions. The financing is intended to be conducted under Kyverna’s existing shelf registration

Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

✨ Onyx Summary Kyverna Therapeutics reported positive topline data from the registrational Phase 2 KYSA-8 trial showing that mivocabtagene autoleucel (miv-cel), a CD19-targeting CAR T-cell therapy, delivered statistically significant and sustained improvements in mobility, disability, and stiffness in patients with stiff person syndrome after a single dose.

ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe

ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe

✨ Onyx Summary The European Medicines Agency recommended granting conditional marketing authorization for ImmunityBio’s ANKTIVA in combination with BCG for patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, marking a potential new treatment option where cystectomy is often the only alternative. The recommendation, based on

Sinaptica Therapeutics Receives Funding from The Centre for Aging + Brain Health Innovation and Baycrest to Advance Breakthrough Neuromodulation Therapy for Alzheimer’s

Sinaptica Therapeutics Receives Funding from The Centre for Aging + Brain Health Innovation and Baycrest to Advance Breakthrough Neuromodulation Therapy for Alzheimer’s

✨ Onyx Summary Sinaptica Therapeutics received funding from the Centre for Aging + Brain Health Innovation (CABHI), in partnership with Baycrest, to support development and validation of its personalized, non-invasive neuromodulation system for Alzheimer’s disease. The funding deepens Sinaptica’s collaboration with Baycrest and supports advancement toward clinical readiness and

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

✨ Onyx Summary Ocugen said CEO and co-founder Dr. Shankar Musunuri will present at the Oppenheimer Movers in Rare Disease Summit on December 11, 2025, where he will discuss the company’s modifier gene therapy platform and its potential applications in inherited retinal and age-related blindness diseases. The presentation,